Taysha Gene Therapies to Participate in Upcoming July Investor Healthcare Conference

July 8, 2021 11:00 UTC

 

William Blair Biotech Focus Conference on July 15, 2021 at 11:00 am ET

 

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a virtual fireside chat for the William Blair Biotech Focus Conference 2021.

Conference's Details:

 

Event:

William Blair Biotech Focus Conference 2021

Date:

Thursday, July 15, 2021

Time:

11:00 am ET

Format:

Fireside chat

Participants:

RA Session II, President, Founder and CEO

 

Dr. Suyash Prasad, Chief Medical Officer and Head of R&D

 

Kamran Alam, Chief Financial Officer

A live webcast of this conference will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. An archived version of the webcast will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Contacts

Company Contact:
Kimberly Lee, D.O.
SVP, Corporate Communications and Investor Relations
Taysha Gene Therapies
klee@tayshagtx.com

Media Contact:
Carolyn Hawley
Canale Communications
carolyn.hawley@canalecomm.com

 
 

Source: Taysha Gene Therapies, Inc.

Back to news